JP2023510871A5 - - Google Patents

Info

Publication number
JP2023510871A5
JP2023510871A5 JP2022542897A JP2022542897A JP2023510871A5 JP 2023510871 A5 JP2023510871 A5 JP 2023510871A5 JP 2022542897 A JP2022542897 A JP 2022542897A JP 2022542897 A JP2022542897 A JP 2022542897A JP 2023510871 A5 JP2023510871 A5 JP 2023510871A5
Authority
JP
Japan
Prior art keywords
wild type
juvenile
deleted
arthritis
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013514 external-priority patent/WO2021146481A1/en
Publication of JP2023510871A publication Critical patent/JP2023510871A/ja
Publication of JP2023510871A5 publication Critical patent/JP2023510871A5/ja
Pending legal-status Critical Current

Links

JP2022542897A 2020-01-14 2021-01-14 Il2ムテイン Pending JP2023510871A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062960847P 2020-01-14 2020-01-14
US62/960,847 2020-01-14
PCT/US2021/013514 WO2021146481A1 (en) 2020-01-14 2021-01-14 Il2 muteins

Publications (2)

Publication Number Publication Date
JP2023510871A JP2023510871A (ja) 2023-03-15
JP2023510871A5 true JP2023510871A5 (https=) 2024-01-22

Family

ID=76863259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542897A Pending JP2023510871A (ja) 2020-01-14 2021-01-14 Il2ムテイン

Country Status (10)

Country Link
US (1) US20230210951A1 (https=)
EP (1) EP4090354A4 (https=)
JP (1) JP2023510871A (https=)
KR (1) KR20220127866A (https=)
CN (3) CN115066253A (https=)
AU (1) AU2021207661A1 (https=)
CA (1) CA3166009A1 (https=)
IL (1) IL294070A (https=)
MX (1) MX2022008770A (https=)
WO (1) WO2021146481A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
EP4357357A4 (en) * 2021-07-30 2025-01-08 Dracoterpin Biomedicine LLC HUMAN INTERLEUKIN-2 VARIANT AND ITS USE
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CA2644513A1 (en) * 2006-03-03 2007-09-07 London Health Sciences Centre Research Inc. Preventing il-2 mediated inflammation in epithelial cells
AU2010206840B2 (en) * 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CA2860170C (en) * 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3538548A4 (en) * 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3707162A1 (en) * 2017-11-10 2020-09-16 Agency for Science, Technology and Research Il2rbeta/common gamma chain antibodies
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
KR20250156190A (ko) * 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2023510871A5 (https=)
RU2464276C2 (ru) Улучшенные нанотела против фактора некроза опухоли-альфа
JP2006516094A5 (https=)
Clements et al. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis
JP2019523653A5 (https=)
JP3328644B2 (ja) 病原性ボレリア・ブルグドルフェリ菌株、病原性ボレリア・ブルグドルフェリの単離及び再培養法
ES2402650T3 (es) Métodos de purificación de anticuerpos anti A beta
US8357778B2 (en) Polypeptide, an affinity chromatography material, and a method for separating and/or purifying immunoglobulin
JP2022020674A5 (https=)
RU2006127314A (ru) Вакцина, стимулирующая рост, основанная на нейтрализующем эпитопе
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2006510619A5 (https=)
DK2000535T3 (da) Sekvenser af circovirus type B forbundet med udmagringssygdom hos pattegrise (PWD).
HRP20150937T1 (hr) Pentaspecifiäśno protutijelo
US20250266122A1 (en) Multi-domain proteins with increased native state colloidal stability
CN113840835A (zh) 结合分子
RU2223115C2 (ru) ГУМАНИЗИРОВАННАЯ АНТИ-Fas АНТИТЕЛОПОДОБНАЯ МОЛЕКУЛА (ВАРИАНТЫ), ДНК (ВАРИАНТЫ), ВЕКТОР (ВАРИАНТЫ), ПОЛИПЕПТИД, СПОСОБ ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЕ АНТИТЕЛА
RU99120702A (ru) Гуманизированная анти-Fas антитело-подобная молекула (варианты), ДНК (варианты), вектор (варианты), полипептид, способ получения, использование антитела
JP2002544237A5 (https=)
JP2006521082A5 (https=)
Yamanaka et al. Cloning and sequence analysis of the hemagglutinin gene of the virulent strain of rinderpest virus
JP2024023268A5 (https=)
Luo et al. Prediction of three-dimensional models for foot-and-mouth disease virus and hepatitis A virus
US10995133B2 (en) Method for producing antibody
JP2023542737A5 (https=)